Research progress of peroxisome proliferators-activated receptors in osteoarthritis

doi:10.3877/cma.j.issn.1674-134X.2023.03.010

Abstract

Abstract:

Osteoarthritis(OA) is a degenerative disease of joint. At present, the specific pathogenesis of OA is not clear. Studies have found that peroxisome proliferator activated receptor (PPAR) can improve the development of OA by correcting the disorder of lipid metabolism, anti-inflammatory, anti chondrocyte apoptosis and other mechanisms. This review aimed to discuss the biological functions of PPAR and their regulatory and therapeutic roles in the development of OA.

Key words: Osteoarthritis, Peroxisome proliferator activated receptor, Metabolism, Inflammation

Zicai Fu, Guandong Dai, Weimin Zhu, Wei Lu, Jianyi Xiong, Daping Wang, Zhenhan Deng. Research progress of peroxisome proliferators-activated receptors in osteoarthritis[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(03): 363-367.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2023.03.010

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2023/V17/I03/363

Figures/Tables 3

Figure 1 PPAR (peroxisome proliferator activated receptor) treats osteoarthritis by correcting lipid metabolism, anti-inflammatory, anti chondrocyte apoptosis and other mechanisms

Figure 2 Structure of PPAR (peroxisome proliferator activated receptor)Note: PPAR has four functional domains, A/B domain: non ligand dependent transcriptional activation domain responsible for PPAR phosphorylation; C domain: DNA binding domain, responsible for the binding of PPAR to the target gene promoter region; D domain: hinge domain combined with auxiliary factors; E/F domain: ligand dependent transcriptional activation domain

Figure 3 Schematic diagram of PPAR mechanism of actionNote: PPAR (peroxisome proliferator activated receptor) and RXR (retinoic acid X receptor) form heterodimer, then form complex with co inhibitor factor or son, and finally with PPRE (peroxisome proliferator response element) to inhibit target gene expression. When PPAR combines with ligand, it combines with co activator to promote target gene transcription

References 35

[1]	王波，余楠生. 膝骨关节炎阶梯治疗专家共识(2018年版)[J/CD]. 中华关节外科杂志(电子版), 2019, 13(1): 124－130.
[2]	Hunter DJ, Bierma-Zeinstra S. Osteoarthritis[J]. Lancet, 2019, 393(10182): 1745－1759.
[3]	Francisco V, Pérez T, Pino J, et al. Biomechanics, obesity, and osteoarthritis. The role of adipokines: when the levee breaks[J]. J Orthop Res, 2018, 36(2): 594－604.
[4]	Ratneswaran A, Sun MM, Dupuis H, et al. Nuclear receptors regulate lipid metabolism and oxidative stress markers in chondrocytes[J]. J Mol Med (Berl), 2017, 95(4): 431－444.
[5]	Cheng HS, Tan WR, Low ZS, et al. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence[J/OL]. Int J Mol Sci, 2019, 20(20): 5055. DOI: 10.3390/ijms20205055.
[6]	杨蓉蓉，张莉，张向颖，等. 过氧化物酶体增殖物激活受体α(PPARα)对脂多糖刺激巨噬细胞引发炎症反应的影响[J]. 中华微生物学和免疫学杂志，2015, 35(6): 431－435.
[7]	Christofides A, Konstantinidou E, Jani C, et al. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses[J/OL]. Metabolism, 2021, 114: 154338. DOI: 10.1016/j.metabol.2020.154338.
[8]	Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications[J]. Eur J Med Chem, 2019, 166: 502－513.
[9]	Bougarne N, Paumelle R, Caron S, et al. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB[J]. Proc Natl Acad Sci U S A, 2009, 106(18): 7397－7402.
[10]	Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets[J]. Cell Biochem Biophys, 2000, 32 Spring: 187－204.
[11]	Berger J, Moller DE. The mechanisms of action of PPARs[J]. Annu Rev Med, 2002, 53: 409－435.
[12]	Zhang J, Liu X, Xie XB, et al. Multitargeted bioactive ligands for PPARs discovered in the last decade[J]. Chem Biol Drug Des, 2016, 88(5): 635－663.
[13]	Amber-Vitos O, Chaturvedi N, Nachliel E, et al. The effect of regulating molecules on the structure of the PPAR-RXR complex[J]. Biochim Biophys Acta, 2016, 1861(11): 1852－1863.
[14]	Ammazzalorso A, de Filippis B, Giampietro L, et al. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview[J]. Chem Med Chem, 2013, 8(10): 1609－1616.
[15]	Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD[J]. Nat Rev Endocrinol, 2017, 13(1): 36－49.
[16]	韩斌，施桥发，王美珍，等. 抵抗素通过PPARγ/NF-κB信号通路调控脂多糖诱导的炎症反应[C]. //第十三届全国免疫学学术大会会议论文，上海，2018.
[17]	Huang H, Wang ZJ, Zhang HB, et al. The function of PPARγ/AMPK/SIRT-1 pathway in inflammatory response of human articular chondrocytes stimulated by advanced glycation end products[J]. Biol Pharm Bull, 2019, 42(8): 1303－1309.
[18]	Alford KA, Glennie S, Turrell BR, et al. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling[J]. J Biol Chem, 2007, 282(9): 6232－6241.
[19]	Hou Y, Moreau F, Chadee K. PPARγ is an E3 ligase that induces the degradation of NFκB/p65 [J/OL]. Nat Commun, 2012, 3: 1300. DOI: 10.1038/ncomms2270.
[20]	Zhao M, Bian YY, Yang LL, et al. HuoXueTongFu formula alleviates intraperitoneal adhesion by regulating macrophage polarization and the SOCS/JAK2/STAT/PPAR-γ signalling pathway[J/OL]. Mediators Inflamm, 2019, 2019: 1769374. DOI: 10.1155/2019/1769374.
[21]	Gou Q, Gong X, Jin J, et al. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy[J]. Oncotarget, 2017, 8(36): 60704－60709.
[22]	Zhou D, Ji L, Chen Y. TSPO modulates IL-4-induced microglia/macrophage M2 polarization via PPAR-γ pathway[J]. J Mol Neurosci, 2020, 70(4): 542－549.
[23]	El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression[J/OL]. Springer Plus, 2016, 5(1): 1508. DOI: 10.1186/s40064-016-3197-y.
[24]	Moqbel SAA, He Y, Xu L, et al. Rat chondrocyte inflammation and osteoarthritis are ameliorated by madecassoside[J/OL]. Oxid Med Cell Longev, 2020, 2020: 7540197. DOI: 10.1155/2020/7540197.
[25]	Seidl CI, Murphy CL. Dual and opposing regulation of MMP1 and MMP13 by both arms of miR-675 in human articular chondrocytes[J]. Cell Physiol Biochem, 2019, 53(1): 172－185.
[26]	Ji B, Ma Y, Wang H, et al. Activation of the P38/CREB/MMP13 axis is associated with osteoarthritis[J]. Drug Des Devel Ther, 2019, 13: 2195－2204.
[27]	Qiu L, Luo Y, Chen X. Quercetin attenuates mitochondrial dysfunction and biogenesis via upregulated AMPK/SIRT1 signaling pathway in OA rats[J]. Biomed Pharmacother, 2018, 103: 1585－1591.
[28]	Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C, et al. Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage[J]. Osteoarthritis Cartilage, 2011, 19(7): 895－902.
[29]	Ratneswaran A, LeBlanc EA, Walser E, et al. Peroxisome proliferator-activated receptor δ promotes the progression of posttraumatic osteoarthritis in a mouse model[J]. Arthritis Rheumatol, 2015, 67(2): 454－464.
[30]	Vasheghani F, Zhang Y, Li YH, et al. PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage[J]. Ann Rheum Dis, 2015, 74(3): 569－578.
[31]	Wang Y, Zhao X, Lotz M, et al. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α[J]. Arthritis Rheumatol, 2015, 67(8): 2141－2153.
[32]	Kim DH, Kim DH, Heck BE, et al. PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-Γ[J]. Regen Ther, 2020, 15: 103－111.
[33]	Zhu X, Chen F, Lu K, et al. PPARγ preservation via promoter demethylation alleviates osteoarthritis in mice[J]. Ann Rheum Dis, 2019, 78(10): 1420－1429.
[34]	Kang S, Zhang J, Yuan Y. Abietic acid attenuates IL-1β-induced inflammation in human osteoarthritis chondrocytes[J]. Int Immunopharmacol, 2018, 64: 110－115.
[35]	François M, Richette P, Tsagris L, et al. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes[J]. Arthritis Rheum, 2006, 54(4): 1233－1245.

Please choose a citation manager

Content to export